FDA green and red lights: July 2024
Darzalex added another string to its bow, while Kisqali’s early use has been delayed.
An unfamiliar name goes after familiar targets
Soon after filing to float in Hong Kong, Baili takes HER2 and DLL3-targeting ADCs into the clinic.
